Pharvaris N.V. $PHVS is Seven Fleet Capital Management LP’s 5th Largest Position

Seven Fleet Capital Management LP lifted its position in Pharvaris N.V. (NASDAQ:PHVS) by 472.3% in the first quarter, Holdings Channel reports. The firm owned 316,697 shares of the company’s stock after acquiring an additional 261,355 shares during the period. Pharvaris accounts for approximately 2.8% of Seven Fleet Capital Management LP’s holdings, making the stock its 5th biggest position. Seven Fleet Capital Management LP’s holdings in Pharvaris were worth $8,947,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after buying an additional 15,769 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares during the period. Legal & General Group Plc boosted its holdings in shares of Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after acquiring an additional 1,695 shares during the period. Amundi grew its position in shares of Pharvaris by 2,741,600.0% during the second quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after acquiring an additional 27,416 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in shares of Pharvaris by 19.2% during the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock worth $860,000 after acquiring an additional 7,879 shares during the last quarter.

Pharvaris Trading Down 3.7%

NASDAQ:PHVS opened at $32.62 on Friday. Pharvaris N.V. has a 12-month low of $19.12 and a 12-month high of $36.60. The stock’s 50 day simple moving average is $32.84 and its 200-day simple moving average is $29.53. The firm has a market cap of $2.13 billion, a P/E ratio of -10.26 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.12. Research analysts forecast that Pharvaris N.V. will post -2.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating on shares of Pharvaris in a research report on Tuesday, June 16th. Wedbush raised their price objective on shares of Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Wolfe Research started coverage on shares of Pharvaris in a research note on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price objective on the stock. Royal Bank Of Canada reduced their target price on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday, April 6th. Finally, Wall Street Zen downgraded shares of Pharvaris from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Pharvaris has a consensus rating of “Moderate Buy” and a consensus price target of $50.08.

Insider Buying and Selling

In other Pharvaris news, Director Robert Glassman sold 10,000 shares of the company’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $29.82, for a total transaction of $298,200.00. Following the completion of the transaction, the director owned 10,500 shares in the company, valued at approximately $313,110. This represents a 48.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Anne Lesage sold 30,703 shares of the firm’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,649.47. Following the completion of the sale, the insider owned 93,969 shares of the company’s stock, valued at $3,334,959.81. This trade represents a 24.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 178,322 shares of company stock worth $5,969,286 in the last ninety days. Insiders own 11.84% of the company’s stock.

Pharvaris Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.